Prevalence of olfactory dysfunction and quality of life in hospitalised patients 1 year after SARS-CoV-2 infection: a cohort study

Hui Qi Mandy Tan 1,2, Alfonso Luca Pendolino 3,4, Peter J Andrews 1,2, David Choi 2

ABSTRACT

Objectives To determine the long-term prevalence of olfactory and/or gustatory dysfunction (OD±GD) and associated risk factors and impact on quality of life (QoL) in previously hospitalised patients with COVID-19 1 year after infection.

Design A single-centre cohort study.

Setting Patients admitted at a large central London hospital with COVID-19 infection between 10 February 2020 and 22 May 2020.

Participants 150 adult subjects with previously confirmed SARS-CoV-2 infection were recruited between 10 December 2020 and 29 January 2021. Patients were predominantly male (102/150, 68.0%); mean age 58.0±15.9 years and 41.2% (56/136) were of black, Asian and minority ethnic backgrounds.

Main outcome measures EQ-5D-5L values and Sino-Nasal Outcome Test-22 (SNOT-22) scores.

Results Long-term prevalence of OD±GD was 12.8% (19/149) at median time of 264.5 days following SARS-CoV-2 infection onset. Patients with OD±GD had a significantly higher median total SNOT-22 score (46.1; Q1–Q3: 23.0–60.0) compared to those without (16.0; Q1–Q3: 5.0–30.5) (95% CI 12.0 to 18.0) (p=0.0002), reflecting poorer QoL, particularly psychological well-being (p=0.0004), which was not alleviated with time (p=0.4977). Median EQ-5D-5L value was not significantly different between patients with OD±GD (0.70; Q1–Q3: 0.38–0.83; 95% CI 0.38 to 0.83) and those without (0.83; Q1–Q3: 0.61–0.94; 95% CI 0.75 to 0.89) (p=0.0627). Age, sex, ethnicity, smoking status, highest C reactive protein value, intubation and ventilation, and oxygen supplementation were not found to influence OD±GD (p>0.05).

Conclusions 12.8% of previously hospitalised patients with COVID-19 in London still report persistent problems with smell or taste up to a year after infection, impacting their QoL. Increased holistic support including psychological therapy and olfactory rehabilitation for affected patients may help to reduce long-term morbidity.

INTRODUCTION

With over 250 million cases and 5 million deaths recorded worldwide so far,1 the COVID-19 pandemic caused by SARS-CoV-2 is an ongoing global crisis. COVID-19 presentation is highly varied. An estimated 17%–20% of those infected remain asymptomatic,2,3 while others can develop a mild-to-moderate disease or severe pneumonia.4

According to WHO, ‘loss of smell or taste’ is considered a less common symptom of COVID-19. However, findings from many studies conducted worldwide have strongly contradicted this, with several reports depicting high prevalence of olfactory and/or gustatory dysfunction (OD±GD) among infected subjects.5–10 So far, the long-term prevalence of OD±GD is unknown, and values determined from the large proportion of studies conducted during the earlier months of the pandemic poorly reflect its persistence and the current proportion of those still affected. Prevalence of OD and GD also vary depending on studied populations,

Strengths and limitations of this study

To our knowledge, this is the first study to have determined the long-term prevalence of olfactory and/or gustatory dysfunction (OD±GD) in a cohort of previously hospitalised patients with COVID-19 at 1 year following infection.

The use of validated measures allows us to conclude that persistent OD±GD, as a key manifestation of long-COVID, is associated with reductions in patient quality of life and well-being.

Prevalence of OD±GD in this study is based on previously hospitalised patients with COVID-19 and may not represent that of mild-to-moderate COVID-19 subjects in the general community, although this allows for important comparisons between different populations.

Patient-reported outcome measures (PROMs) poorly correlate with psychophysical tests. However, given their good discriminative ability to predict an impaired olfactory function, PROMs still remain of value when psychophysical testing cannot be conducted.
between 54.2% and 70.2% of the general population with mild-to-moderate symptoms (mean 11.5±5.7 days), 69.2% and 73.1% in mild-to-moderate symptomatic healthcare workers (median follow-up of 52 days), 29 and 5.1% and 5.6% in acutely hospitalised patients. 12 There also remains conflicting data surrounding associated risk factors. Pre-COVID-19 data show that OD is associated with increased morbidity and mortality, 13–15 and population studies have shown that anosmia is an independent risk factor for a shortened life span. 16–20 In a study of over 3000 adults, olfactory function was reported to be one of the strongest independent predictors of 5-year mortality, surpassing heart failure, lung disease and even cancer. 21 COVID-19-related OD presentation has been extensively investigated, but its impact on quality of life (QoL) in the context of COVID-19 has not been fully explored. Therefore, this represents a key area which needs to be addressed to more effectively reduce long-term morbidity.

We conducted a cohort study on previously hospitalised patients with COVID-19 admitted at a central London hospital during the first pandemic wave, to determine the long-term prevalence of OD±GD, potential risk factors and impact on QoL.

METHODS
A cohort study of previously hospitalised patients with COVID-19 was performed between 10 December 2020 and 29 January 2021 at the National Hospital for Neurology and Neurosurgery (London, UK).

Study population
Three hundred and fifty-eight patients hospitalised at University College London Hospital with a COVID-19 diagnosis between 10 February 2020 and 22 May 2020 were identified as potentially eligible for this study. Sample size was determined pragmatically based on data available within the medical database at the time of collection. Electronic medical records and laboratory findings were reviewed to verify full adherence to the following inclusion criteria: (1) adults ≥18 years of age, and either (2) laboratory-confirmed SARS-CoV-2 infection, defined as a positive result on reverse transcription PCR analysis of nasopharyngeal swab specimens, or (3) clinically confirmed COVID-19 on the basis of presenting symptoms, in accordance with WHO interim guidance at the time. 22 Considering the lack of widespread testing in the UK during this studied period of the pandemic, both laboratory and clinical diagnostic criteria were initially included to prevent inadvertent exclusion of eligible participants. Prior to commencement of the study, demographic data including age, sex, ethnicity and smoking status were noted to facilitate investigation into any potential associations. Baseline characteristics and medical status were also recorded to identify ineligible patients (death or patient age <18 years).

Outcomes
Eligible subjects were invited to undertake telephone interviews involving a series of standardised questions from validated questionnaires: the EuroQoL 5-Dimension 5-Level (EQ-5D-5L) 23 and the Sino-Nasal Outcome Test-22 (SNOT-22). Patients reporting decreased sense of smell/taste in the SNOT-22 were subsequently followed up with an additional smell and taste questionnaire (online supplemental figure 1) designed to capture specific details relating to the type(s) of chemosensory dysfunction experienced. All telephone interviews were conducted in English by the same researcher following a standardised procedure in an effort to minimise interobserver bias. Verbal informed consent was obtained from all participants prior to enrolment in the study.

Statistical analysis
All statistical analyses were performed using GraphPad Prism V.9.0.1 for macOS (GraphPad Software, San Diego, California, USA). Qualitative variables were presented as frequency and percentages; quantitative variables were summarised as median and IQR or mean±SD for normally distributed data. Non-parametric variables were compared using the Mann-Whitney test; data following Gaussian distribution were analysed using the unpaired t-test, with Welch’s correction applied to adjust for unequal SDs and variances. Fisher’s exact test was used to compare associations between variables in patients with OD±GD and patients without OD or GD. Linear regression analysis was performed to explore whether SNOT-22 scores changed over time. The 95% CIs were provided for the reported data where appropriate, and the level of statistical significance was set at a two-sided p<0.05.

Patient and public involvement
No patients or members of the public were involved in setting the research question or the outcome measures. They were not involved in the study design or conduct, nor were they invited to contribute to the writing, interpretation, reporting or distribution of the results.

RESULTS
Three hundred and fifty-eight patients previously hospitalised with a COVID-19 diagnosis were identified as potentially eligible for this study. Figure 1 outlines the selection process. Following screening of electronic medical records for all 358 patients, 141 were classed as ineligible and subsequently excluded. This comprised patients who had either died (n=129) or those <18 years of age (n=1), as well as patients with a COVID-19 negative diagnosis (n=11), defined as individuals with presenting complaints initially ascribed to SARS-CoV-2 infection, but which were later attributed to non-COVID-19 causes. The remaining 217 patients were deemed eligible for this study. However, 15 were not invited to participate due to overarching causes for exclusion. This included patients who were unable to consent, such as those with severe cognitive impairment (n=9), severe learning disabilities (n=3) or patients under intensive hospitalisation (n=1). Additionally, imprisoned individuals (n=1) and those...
with explicit refusal to partake in research as recorded in the patient notes (n=1) were excluded. Of the 202 patients contacted and invited to participate, 51 were excluded. This included unreachable patients (n=13), defined as those unable to be contacted despite >3 separate attempts (n=5) and those with invalid contact details (n=8). Patients with communication difficulties (n=3) referring to aphasis (n=2) or patients with hearing impairments (n=1) preventing completion of the questionnaires. Responses were received from 151/202 invited participants, thereby resulting in a response rate of 74.8%. One patient who did not provide any answers to the SNOT-22 was excluded.

Demographics and characteristics

A final population of 150 subjects (102 male and 48 female, male:female ratio of approximately 2:1) was obtained. The majority of patients had laboratory-confirmed COVID-19 (n=147) and three patients had a presumptive diagnosis based on clinical criteria. Median time from infection was 264.5 days (range 215–318). Detailed demographics and baseline characteristics of the population are summarised in table 1.

Sino-Nasal Outcome Test-22

A total of 150 patients completed the SNOT-22 and the median total score for the whole population was 17.0 (Q1–Q3: 6.0–36.3; 95% CI 13.0 to 22.0). As depicted in figure 2, the five most prevalent SNOT-22 problems were: wake up tired (101/149, 67.8%), fatigue (97/147, 66.0%), lack of a good night’s sleep (98/149, 65.8%), reduced productivity (97/148, 65.5%) and wake up at night (94/149, 63.1%). Wake up tired, fatigue and lack of a good night’s sleep were also among the problems most frequently reported to affect patient health the most (figure 3). 14.1% (21/149) of patients reported to have decreased sense of smell/taste in the SNOT-22 (score ≥1 at the corresponding item), of which the severity was very mild in 4.0%, mild in 4.7%, moderate in 2.7% and severe in 2.7%. Two individuals were classed as pre-existing OD±GD based on evidence of iatrogenic causes and age-related olfactory loss predating COVID-19 infection and hospitalisation. This led to a total of 19/149 patients (12.8%) with reported decreased smell/taste in the context of COVID-19. Only 2/18 (11.1%) had sought treatment: one patient did olfactory training and the other patient did not specify. Characteristics of OD and GD are reported in table 2.

Patients with OD±GD demonstrated a statistically significant higher median total SNOT-22 score (46.1; Q1–Q3: 23.0–60.0; 95% CI 23.0 to 60.0) than those without (16.0; Q1–Q3: 5.0–30.5; 95% CI 12.0 to 18.0) (p=0.0002) and their scores were higher across all SNOT-22 domains except one (extranasal rhinologic symptoms) (table 3). Total SNOT-22 scores were found to improve over time in patients without OD or GD (p=0.0327), although this was not observed in patients with OD±GD (p=0.4977) (figure 4). Comparisons of the demographics of the two subgroups found no influence of age, sex, ethnicity or smoking status (have smoked...
vs never smoked) on the development of OD±GD (p>0.05) (table 1). Similarly, no statistically significant association was observed between OD±GD and other characteristics recorded during hospitalisation, such as highest C reactive protein (CRP) value, requirement for intubation and ventilation, or oxygen supplementation (p=0.9282, 0.7263 and 0.4599, respectively).

**EQ-5D-5L**
A total of 149 patients completed the EQ-5D-5L and the median value for the total population was 0.80 (Q1–Q3: 0.53–0.94; 95% CI 0.73 to 0.86). Patients with OD±GD had a lower median EQ-5D-5L value (0.70; Q1–Q3: 0.38–0.83; 95% CI 0.38 to 0.83) compared with those without OD or GD (0.83; Q1–Q3: 0.61–0.94; 95% CI 0.75 to 0.89); however, the difference was not statistically significant (p=0.0627). Time from infection (the number of days between the date of the patient’s first COVID-19 positive swab or their onset of COVID-19 symptoms, and the date at which the questionnaire was administered) was not found to be correlated to EQ-5D-5L value in both patients.

### Table 1  Detailed characteristics of the population

|                          | Total population | Patients without OD or GD | Patients with OD±GD | P value |
|--------------------------|------------------|---------------------------|---------------------|---------|
| Age, (mean±SD), years    | 58.0±15.9        | 57.8±16.4                 | 59.6±11.8           | 0.5773  |
| Age groups, n (%)        |                  |                           |                     |         |
| 18–30                    | 5 (3.3)          | 5 (3.9)                   | 0 (0)               |         |
| 31–40                    | 20 (13.3)        | 18 (14.0)                 | 2 (10.5)            |         |
| 41–50                    | 25 (16.7)        | 21 (16.3)                 | 3 (15.8)            |         |
| 51–60                    | 23 (15.3)        | 21 (16.3)                 | 2 (10.5)            |         |
| 61–70                    | 48 (32.0)        | 37 (28.7)                 | 11 (57.9)           |         |
| 71–80                    | 15 (10.0)        | 14 (10.9)                 | 0 (0)               |         |
| 81–90                    | 12 (8.0)         | 11 (8.5)                  | 1 (5.3)             |         |
| >90                      | 2 (1.3)          | 2 (1.6)                   | 0 (0)               |         |
| Sex, n (%)               |                  |                           |                     |         |
| Male                     | 102 (68.0)       | 90 (68.8)                 | 11 (57.9)           | 0.3032  |
| Female                   | 48 (32.0)        | 39 (30.2)                 | 8 (42.1)            |         |
| Ethnicity, n (%)*        |                  |                           |                     | >0.9999 |
| White                    | 80 (58.8)        | 68 (58.6)                 | 11 (61.1)           |         |
| BAME                     | 56 (41.2)        | 48 (41.4)                 | 7 (38.9)            |         |
| Missing                  | 14               | 13                        | 1                   |         |
| Smoking status, n (%)*   |                  |                           |                     |         |
| Never smoked             | 72 (65.5)        | 64 (66.7)                 | 7 (53.8)            |         |
| Have smoked              | 38 (34.5)        | 32 (33.3)                 | 6 (46.2)            |         |
| Current                  | 10 (9.1)         | 9 (9.4)                   | 1 (7.7)             | 0.3699  |
| Quit                     | 28 (25.5)        | 23 (24.0)                 | 5 (38.5)            |         |
| Missing                  | 40               | 33                        | 6                   |         |
| Highest CRP value (mean±SD), mg/L | 170.9±135.6 | 174.5±139.5 | 158.0±109.5 | 0.9282 |
| Intubation and ventilation, n (%)* | 52 (57.8) | 44 (55.7) | 6 (66.7) | 0.7263 |
| Yes                      | 38 (42.2)        | 35 (44.3)                 | 3 (33.3)            |         |
| Missing                  | 60               | 50                        | 10                  |         |
| Oxygen supplementation, n (%)* | 20 (17.2) | 18 (17.8) | 1 (7.1) | 0.4599 |
| No                       | 96 (82.8)        | 83 (82.2)                 | 13 (92.9)           |         |
| Yes                      | 34               | 28                        | 5                   |         |
| Missing                  |                  |                           |                     |         |

Percentages may not total 100.0% due to rounding.
*Missing data have been reported but were not used in the calculation of percentages (valid percent).
BAME, black, Asian and minority ethnic; CRP, C reactive protein; OD±GD, olfactory and/or gustatory dysfunction.
Figure 2  Prevalence of Sino-Nasal Outcome Test-22 (SNOT-22) problems stratified by severity and categorised by domain. †The item ‘decreased sense of smell/taste’ was excluded from the rhinologic symptoms domain and presented separately, given olfactory and/or gustatory dysfunction (OD±GD) status was used as a subgroup in the subanalysis.

Figure 3  SNOT-22 problems reported to most greatly affect patient health. OD±GD, olfactory and/or gustatory dysfunction; SNOT-22, Sino-Nasal Outcome Test-22.
DISCUSSION

This is the first study to evaluate the long-term prevalence of OD±GD in a group of previously hospitalised patients with COVID-19.

The prevalence of OD±GD in our studied population was 12.8%. This is considerably lower than that of surveys conducted in hospitalised patients in Europe (35.0%–80.6% for OD and 21.0%–90.3% for GD within 1 month),25–27 and in other countries such as Turkey (42.3% for OD±GD),28 and Brazil (64.6% and 66.7% for OD and GD, respectively, at follow-up of 15–55 days).29

The longer follow-up at which our study has been conducted could explain the lower rate of observed chemosensory alteration in our population, whereby recovery of OD/GD is expected to happen over time in some patients. This is supported by a recent French study which found that 24.0% of non-severe COVID-19 subjects reported persistent OD/GD 7 months after symptom

Table 2 Prevalence and characteristics of olfactory and gustatory disorders

| Total responses (n=149) |
|------------------------|
| Prevalence, n (%)      |
| Total reporting decreased smell/taste 21 (14.1) |
| In the context of COVID-19 19 (12.8) |
| Pre-existing 2 (1.3) |
| No OD or GD 128 (85.9) |
| Analysed population with OD±GD (n=19)* |

| Type of dysfunction reported, n (%) |
|-----------------------------------|
| OD and GD 15 (78.9) |
| Only OD 4 (21.1) |
| Only GD 0 (0) |
| Parosmia† 3 (16.7) |
| Parageusia† 5 (27.8) |
| Phantosmia† 2 (11.1) |
| Phantogeusia† 0 (0) |

| OD±GD characteristics, n (%) |
|------------------------------|
| Constant† 14 (77.8) |
| Fluctuant† 4 (22.2) |
| Isolated OD†‡ 1 (5.3) |
| Isolated GD†‡ 0 (0) |

| Treatment, n (%)† |
|-------------------|
| Have not sought treatment 16 (88.9) |
| Have sought treatment 2 (11.1) |

*Analyses performed on population following application of exclusion criteria (excludes pre-existing OD±GD).
†Valid percentages calculated based on subjects who provided responses to the question (n=18). Missing responses were not included in the calculations.
‡’Isolated’ OD or GD defined as decreased sense of smell/taste in the absence of any other SNOT-22 problem.

OD±GD, olfactory and/or gustatory dysfunction; SNOT-22, Sino-Nasal Outcome Test-22.

Table 3 Subgroup differences in median total SNOT-22 score for each domain

| Domain                  | Median total SNOT-22 score | Patients without OD or GD (n=129) | Patients with OD±GD (n=19) | P value |
|-------------------------|-----------------------------|-----------------------------------|-----------------------------|---------|
| Rhinologic symptoms     | 2.0                         | 6.0                               | 0.0189*                     |
| Extranasal rhinological symptoms | 0 | 1.0                           | 0.0524                     |
| Ear/facial symptoms     | 1.0                         | 3.75                              | 0.0087**                   |
| Psychological dysfunction| 7.0                         | 22.0                              | 0.0004***                  |
| Sleep dysfunction       | 6.0                         | 16.0                              | 0.0024**                   |

Significant p values in bold. Level of significance *p<0.05, **p<0.01, ***p<0.001.

OD±GD, olfactory and/or gustatory dysfunction; SNOT-22, Sino-Nasal Outcome Test-22.
onset.30 Interestingly, our prevalence of 12.8% is similar to that observed by Lee et al.31 (15.3%) in a large Korean cohort of 3191 patients with varying COVID-19 severity at 1 month, but it is relatively higher than that observed by Mao et al.32 in a population of 214 acutely hospitalised patients with COVID-19 (5.1% and 5.6% with OD and GD, respectively). A selection bias could have potentially influenced the observed lower prevalence. Most surveys investigating OD/GD in COVID-19 subjects have been conducted on patients with mild-to-moderate symptoms.31–34 In this regard, higher prevalence of anosmia has been noted in milder individuals, along with a significantly increased risk of self-reported olfactory loss in outpatients compared with hospitalised patients.35 This is reflected in the most recent studies on long-term COVID-19-related OD+GD. In one study, 48.0% and 38.5% of non-hospitalised COVID-19 subjects reported persistent OD and GD, respectively, at 8 months follow-up.36 Similarly, 21.3% of subjects reported OD+GD in another study of mild-to-moderate symptomatic patients at 1 year.37 These values were notably higher than our described prevalence despite the longer follow-up times, thus suggesting that selection bias may produce the observed disparities in reported long-term OD+GD prevalence.

Additionally, it is important to consider the possible contribution of COVID-19 variants to such disparities due to their potential differing effects on olfaction. Genetic, structural and epidemiological data have shown that a single nucleotide polymorphism from D614 to G614 (D614G mutation) in the spike protein of SARS-CoV-2 may enhance chemosensory impairment, resulting in increased prevalence of COVID-19-related OD+GD.38–39 With the presence of different viral strains and potentially uncharacterised host and viral variants, such factors may have therefore contributed to the different incidences of OD+GD observed between countries.

In our population, OD was associated with GD in most of the cases (78.9%), while none of the subjects reported GD only. This reflects what has extensively been reported in previous studies30–41 and confirms that GD is usually linked to an impairment of retronasal olfaction rather than impairment of gustation itself. Nonetheless, although less common, isolated GD has been described in patients with COVID-19.45

Despite the extensive literature available on quantitative changes in smell and taste, qualitative alterations of smell and taste in COVID-19 have been seldom explored. In our study, 16.7% of patients had parosmia (distortions in smell) while 27.8% had parageusia (distortions in taste). A similar prevalence (15.0%) of parosmia was reported by Gorzkowski et al.43 although a higher rate of 32.4% was previously described by Lechien et al.5 Prevalence of COVID-19-related parageusia vary widely in the literature, but a recent meta-analysis of 8438 patients with COVID-19 from 13 countries revealed a pooled prevalence of 38.2% (95% CI 24.0% to 53.6%),44 which is higher than that observed in our study. The differences observed between studies could partly reflect inherent biases in the composition of sampled populations. Additionally, a cultural variability in taste appreciation or perception has been reported to exist in COVID-19 positive subjects with a different cultural background.45 Phantosmia (the detections of smells not present within the environment) was reported in 11.1% of our study participants. A similar prevalence was reported by Lechien et al.46 and Gorzkowski et al.43 No cases of phantogeusia (abnormal taste in the mouth in the absence of any stimulus) were recorded in our population and based on the current published literature, prevalence of phantogeusia in COVID-19 subjects is unknown. In line with previous findings,5,43 most of our participants (77.8%) reported constant OD+GD, suggesting that the driving mechanism leading to persistent chemosensory dysfunction is sensorineural.

No statistically significant association between persistent OD±GD and age, smoking status, highest CRP value, intubation and ventilation, or oxygen supplementation was found in our study, thus corroborating results from multiple studies.29,30,43,46–50 Similarly, sex did not demonstrate any influence on the prevalence of persistent OD±GD in our study, which is in line with previous studies conducted worldwide.5,32,43,47,51,52 Nonetheless, several authors have described a significantly higher prevalence of OD±GD in women,5,31,40,55 with some reports suggesting that being female is a risk factor for prolonged recovery from chemosensory dysfunction.20,46 However, the female predominance observed from such studies may be attributed to the differences in the sampled populations (hospitalised vs mild-to-moderate) or in the gender composition. In fact, previous studies on COVID-19 hospitalised patients have demonstrated a lower prevalence of female patients,54 which is confirmed by the male:female ratio in our population (2:1). Moreover, women tend to outperform men on olfactory assessment and in their capacity to perceive OD, which could lead to disproportionately increased prevalence seen in females.35–36

Our study included a more ethnically diverse population in comparison to more geographically limited studies conducted on cohorts of the same ethnic background.

![Figure 5](Image) Linear regression analysis of EQ-5D-5L value and time from infection in patients with OD±GD and patients without OD or GD. OD±GD, olfactory and/or gustatory dysfunction; EQ-5D-5L, EuroQoL 5-Dimension 5-Level.
Despite this, we found no statistically significant association between ethnicity and OD±GD, in contrast to what was reported by Doty before the pandemic that ethnic minorities are more at risk of developing chemosensory dysfunction.

In this study, the majority of patients reporting decreased sense of smell/taste had very mild or mild impairment as opposed to moderate or severe impairment. Decreased sense of smell/taste was also not frequently ranked within the top five of their most important items, suggesting that chemosensory impairment was not of their greatest concern, if compared with other residual symptoms listed in the SNOT-22. This is an expected finding, considering previous studies which show that hospitalised patients are less likely to report olfactory loss compared with patients with milder course, possibly due to the presence of more prominent symptoms. However, while OD±GD severity was not largely found to be profound in this study, it should be noted that patients with OD±GD had a significantly higher median total SNOT-22 score than those without, with the score only improving over time for the latter subgroup. This corresponds to a greater health burden and subsequent poorer QoL among those affected with chemosensory impairments, as exemplified in a recent study by Chary et al. More importantly, it reflects the ongoing health burden in patients with OD±GD, which has previously been depicted to a similar effect. Analysis of the SNOT-22 items demonstrated intrinsic psychological and sleep dysfunction in our population, where the items wake up tired, fatigue and lack of a good night’s sleep were three of the most commonly ticked ‘important items’ (maximum of five items). While this highlights some of the long-term manifestations of COVID-19, now called ‘long-COVID’, further subanaylsis revealed that OD±GD reduced QoL in nearly all domains, especially that of psychological dysfunction, when compared with patients without OD or GD. Recent studies have supported this, with emphasis on both the direct and indirect negative effects of COVID-19-related OD on psychological well-being. In one study, 15.8% of patients with COVID-19 with OD reported depression due to their smell loss, whereas in a separate study, 28.2% had increased anger as a secondary effect. A more recent study reported that chemosensory disturbance in mildly symptomatic patients with COVID-19 was associated with emotional distress and depression, despite over a year since the onset of their COVID-19 infection. Interestingly, long-lasting fatigue has also been found to be significantly associated with persistent OD±GD. Taken together, our findings therefore highlight the negative long-term effects of persistent OD±GD on QoL.

Conversely, based on subgroup analysis of EQ-5D-5L values, we did not observe any difference in health-related QoL between those with OD±GD and those without. More importantly, EQ-5D-5L value did not improve with time and was not influenced by the presence of a chemosensory alteration. One possible explanation for these results is interpatient variability. Given that the EQ-5D-5L is nonspecific to COVID-19 and captures responses based on overall QoL on the day of questioning, patients’ responses could have been influenced by other factors. The questionnaire also may not have been sensitive enough to differentiate the problems experienced by patients with OD±GD. Alternatively, the lack of any significant difference in EQ-5D-5L values between these two subgroups may reflect the residual difficulties of long-COVID which are common to many patients with COVID-19, regardless of anosmia status.

Strengths and limitations

To our knowledge, this represents the first study to have determined the prevalence of OD±GD in a cohort of previously hospitalised patients with COVID-19 at 1 year following infection. We have, therefore, provided a more current insight into both the persistence and the scale of OD and GD from a long-term perspective, and the impact on patients’ QoL and well-being. Our cohort of previously hospitalised patients with COVID-19 also adds value by highlighting differences in OD±GD prevalence in different populations, given that current existing studies have predominantly been based on mild-to-moderately affected patients or healthcare workers.

The prevalence of OD and GD observed in our study refers to a single-centre population of previously hospitalised patients with COVID-19. Our findings, therefore, may not be directly comparable or generalisable to those reported for mild-to-moderate symptomatic COVID-19 subjects in the general community. There is also the possibility of misdiagnosis, especially with the three clinically confirmed patients with COVID-19, although this is unlikely considering the surging number of COVID-19 cases at the time of their presentation. Without baseline data, we were unable to determine the extent to which the impairments in OD±GD patients were new onset or more chronic, or whether there was any previous improvement of chemosensory function. Lastly, as in other COVID-19 studies, patients with OD±GD were identified through subjective, self-reported questionnaires. These have a low correlation with psychophysical measurements, and findings derived from these surveys cannot be compared with studies which have used objective tests, such as Sniffin’ sticks. However, given that psychophysical testing has not been available or feasible in many countries during the pandemic, we believe that, in an emergency condition, self-rated symptoms remain of value.

Clinical implications of this study

A proportion of previously hospitalised patients with COVID-19 may continue to experience persistent OD±GD long term, especially when this is not treated. With over 9.3 million COVID-19 positive cases in the UK at the time of writing, and with numbers likely to increase including untested asymptomatic individuals and those with milder disease, our study demonstrates the relevance of OD±GD and its place as a key manifestation of long-COVID. OD±GD impacts QoL and can have a potentially

Tan HQM, et al. BMJ Open 2022;12:e054598. doi:10.1136/bmjopen-2021-054598.
substantial long-term burden on patients and healthcare resources.

Our study suggests that persistent COVID-19-related chemosensory dysfunction requires increased holistic support. This includes safety counselling, psychological therapy, coping strategies and patient support groups to aid patients in the management of their OD±GD, but concurrent rehabilitation such as olfactory training should also be considered, given the evidence base supporting its effectiveness in post-viral olfactory loss.65–68

It should also be noted that there are currently ongoing clinical trials assessing other interventions such as anti-inflammatory agents, nasal/oral steroids and even intra-nasal photobiomodulation therapy.69 70 However, while these could play supportive roles in the potential recovery of COVID-19-related OD±GD, further research regarding their safety and efficacy will be needed, alongside additional studies investigating the impact of such modalities on patient QoL.

CONCLUSIONS

Up to a year following infection, 12.8% of previously hospitalised patients with COVID-19 in London reported persistent chemosensory dysfunction. COVID-19-related OD±GD reduces both QoL and psychological wellbeing, and this does not improve over time, creating an important health burden. With the number of patients seeking treatment expected to rise, developing new therapeutic treatments will be important in the future, as well as providing adequate support patient for now.

Contributors DC and HQMT conceptualised and designed the study. HQMT and ALP drafted the manuscript. HQMT performed data acquisition, statistical analyses and production of figures and tables. All authors (HQMT, ALP, PJA and DC) contributed to the interpretation of the results and critically revised the manuscript. All authors approved the final manuscript. The corresponding author (HQMT) attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. HQMT and DC are the guarantors.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not applicable.

Ethics approval This study involves human participants and was approved by Research Ethics Committee and the UCL Joint Research Office (REC reference: 14/SC/1180; IRAS project ID: 156511).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement No data are available. No additional data are available.

Supplemental material This content has been supplied by the authors(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES

1 World Health Organization. WHO Coronavirus (COVID-19) Dashboard [Internet]. 2021. Available: https://covid19.who.int [Accessed 10 Nov 2021].

2 Buitrago-García D, Egli-Gany D, Cournotte MJ, et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: a living systematic review and meta-analysis. PLoS Med 2020;17:e1003346.

3 Byambasuren G, Cardona M, Bell K. Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: systematic review and meta-analysis. JAMA 2020;323:334–41.

4 Struyf T, Deeks JJ, Dinesse J, et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19. Cochrane Database Syst Rev 2021;2:CD013665.

5 Lechien JR, Chiesa-Estomba CM, De Slati DR, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol 2020;277:2251–61.

6 Qiu C, Cui C, Hautefort C, et al. Olfactory and gustatory dysfunction as an early identifier of COVID-19 in adults and children: an international multicenter study. Otolaryngol Head Neck Surg 2020;162:714–21.

7 Moen ST, Haasen-Assmann SM, Mansourafshar B, et al. Smell dysfunction: a biomarker for COVID-19. Int Forum Allergy Rhinol 2020;10:944–50.

8 Samaranayake LP, Fakhruddin KS, Mohammad OE, et al. Attributes of dysgeusia and anosmia of coronavirus disease 2019 (COVID-19) in hospitalized patients. Oral Dis 2020. doi:10.1111/odi.13713. [Epub ahead of print: 11 Nov 2020].

9 Andrews PJ, Pendolino AL, Ottaviano G, et al. Olfactory and taste dysfunction among mild-to-moderate symptomatic COVID-19 positive health care workers: an international survey. Laryngoscope Investig Otolaryngol 2020;5:1019–26.

10 Chiesa-Estomba CM, Lechien JR, Radulescu T, et al. Patterns of smell recovery in 751 patients affected by the COVID-19 outbreak. Eur J Neurol 2020;27:2318–21.

11 Lechien JR, Chiesa-Estomba CM, Place S, et al. Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. J Intern Med 2020;288:335–44.

12 Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. Jama Neurol 2020;77:983–90.

13 Croy I, Nordin S, Hummel T. Olfactory disorders and quality of life--an updated review. Chem Senses 2014;39:185–94.

14 Nordin S, Brämerson A. Complaints of olfactory disorders: epidemiology, assessment and clinical implications. Curr Opin Allergy Clin Immunol 2008;8:10–15.

15 Landis BN, Konnerth CG, Hummel T. A study on the frequency of olfactory dysfunction. Laryngoscope 2004;114:1764–9.

16 Devanand DP, Lee S, Manly J, et al. Olfactory identification deficits and increased mortality in the community. Ann Neurol 2015;78:401–11.

17 Schubert CR, Fischer ME, Pinto AA, et al. Sensory impairments and risk of mortality in older adults. J Gerontol A Biol Sci Med Sci 2017;72:710–5.

18 Liu B, Luo Z, Pinto JM, et al. Relationship between poor Olfaction and mortality among community-dwelling older adults: a cohort study. Ann Intern Med 2019;170:673–81.

19 Laudisio A, Navarini L, Margiotta DPE, et al. The association of olfactory dysfunction, frailty, and mortality is mediated by inflammation: results from the InCHIANTI study. J Immunol Res 2019;2019:3128231.

20 Ekström I, Šjölund S, Nordin S, et al. Smell loss predicts mortality risk regardless of dementia conversion. J Am Geriatr Soc 2017;65:1238–43.

21 Pinto JM, Wroblewski KE, Kern DW, et al. Olfactory dysfunction predicts 5-year mortality in older adults. PLoS One 2014;9:e107541.
Pendolino AL, Ottaviano G, Scarpa B. Characteristics of taste dysfunction in COVID-19 subjects coming from two different countries. J Neurovirol 2021;1-4.

Chary E, Carsuzaa F, Trioloet J-P et al. Prevalence and recovery from olfactory and gustatory dysfunctions in Covid-19 infection: a prospective multicenter study. Am J Rhinol Allergy 2020;34:686–93.

Otto MS, Klussmann JP, Luers JC. Persisting olfactory dysfunction in patients after recovering from COVID-19. J Infect 2020;81:e558.

Paderno A, Mattavelli D, Rampinelli V et al. Olfactory and gustatory outcomes in COVID-19: a prospective evaluation in nonhospitalized subjects. Otolaryngol Head Neck Surg 2020;163:1144–9.

Ugurlu BN, Akdogan O, Yilmaz YA et al. Quantitative evaluation and prognostic role of olfactory dysfunction in COVID-19. Eur Arch Otorhinolaryngol 2021;278:2363–9.

Sakali E, Temirbekov D, Bayr et al. Ear nose throat-related symptoms with a focus on loss of smell and/or taste in COVID-19 patients. Am J Otolaryngol 2020;41:102622.

Otto MS, Eckel HNC, Poluschkin L et al. Olfactory dysfunction in patients after recovering from COVID-19. Acta Otolaryngol 2021;140:1032–5.

Vaira LA, Hopkins C, Petrocelli M et al. Smell and taste recovery in coronavirus disease 2019 patients: a 1-year objective and prospective study. J Laryngol Otol 2020;134:703–9.

Hopkins C, Surda P, Whitehead E et al. Early recovery following new onset anosmia during the COVID-19 pandemic - an observational cohort study. J Otolaryngol Head Neck Surg 2020;49:26.

Rinoxyo H, de Grujter CJM, Raine C et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun 2020;11:6317.

Doty RL, Cameron EL. Sex differences and reproductive hormone influences on human odor perception. Physiol Behav 2008;97:213–28.

Kosugi EM, Lavinsky J, Romano FR et al. Incomplete and late recovery of sudden olfactory dysfunction in COVID-19. Braz J Otorhinolaryngol 2020;86:490–6.

Doty RL. Chapter 1 - Epidemiology of smell and taste dysfunction. In: Doty RL, ed. Handbook clin Neurol. 2019; 164, 3–13.

Mandal S, Barnett J, Brill SE et al. ‘Long-COVID’: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax 2021;76:396–9.

Elkojhi SMA, Abdelwahab MK, Abdelhameez M. Impact of the smell loss on the quality of life and addiction in patients with COVID-19. Eur Arch Otorhinolaryngol 2021;278:3307–14.

AilShahk A, Almomen A, AlYaeesa I et al. The association of smell and taste dysfunction with COVID19, and their functional impacts. Indian J Otolaryngol Head Neck Surg 2021;1-6.

Boscolo-Rizzo P, Hummel T, Hopkins C et al. High prevalence of long-term olfactory, gustatory, and chemesthesia dysfunction in post-COVID-19 patients: a matched case-control study with one-year follow-up using a comprehensive psychophysical evaluation. J Neurol 2020;267:1225–33.

Bordin A, Mucignat-Caretta G, Gaudioso P et al. Comparison of self-reported symptoms and psychophysiological tests in coronavirus disease 2019 (COVID-19) subjects experiencing long-term olfactory dysfunction: a 6-month follow-up study. Int Forum Allergy Rhinol 2021;11:1597–609.

Prajapati DP, Shahrvini B, MacDonald BV et al. Association of subjective olfactory dysfunction and 12-Item odor identification testing in ambulatory COVID-19 patients. Int Forum Allergy Rhinol 2020;10:1209–17.

Cases in the UK | Coronavirus in the UK [Internet]. Available: https://coronavirus.data.gov.uk/details/cases [Accessed 10 Nov 2021].

Levy JM. Treatment recommendations for persistent smell and taste dysfunction following COVID-19: The coming deluge. JAMA Otolaryngol Head Neck Surg 2020;146:733.

Whitcroft KL, Hummel T. Clinical diagnosis and current management strategies for olfactory dysfunction: a review. JAMA Otolaryngol Head Neck Surg 2019;145:846–9.

Whitcroft KL, Hummel T. Olfactory dysfunction in COVID-19: diagnosis and management. JAMA 2020;323:2512–14.

Hummel T, Whitcroft KL, Andrews P et al. Post COVID-19 olfactory dysfunction. Rhinol Suppl 2017;54:1–30.

D’Asciano L, Vitelli F, Cingolani C et al. Randomized clinical trial ‘olfactory dysfunction after COVID-19: olfactory rehabilitation therapy vs. Intervention treatment with Palmitoylethanolamide and Luteolin’: preliminary study. Eur Rev Med Pharmacol Sci 2021;25:4156–62.

Soares LES, Guirado MMG, Berlingeri G et al. Intranasal photobiomodulation therapy for COVID-19-related olfactory dysfunction: A Brazilian multicenter case series. Photodiagnosis Photodyn Ther 2021;36:102574.